Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8151 to 8183 of 8183 results

  1. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  2. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]

    In development [GID-TA11006] Expected publication date: 29 May 2024

    Technology appraisal guidance
    In development

  3. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  4. Surgical Insertion of a Catheter based intravascular microaxial blood pump

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  5. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  6. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  7. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 21 May 2025

    NICE guideline
    In development

  8. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

    In development [GID-HTE10035] Expected publication date: TBC

    Health technology evaluations
    In development

  9. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  10. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment

    In development [GID-HTE10019] Expected publication date: 25 April 2024

    Health technology evaluations
    In development

  14. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 16 May 2024.

    Technology appraisal guidance
    In consultation

  15. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405: draft scope consultation

    We are listening to your views on this Health technology evaluation. Comments close 23 May 2024.

    Health technology evaluation
    In consultation

  16. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 04 June 2024

    Technology appraisal guidance
    In development

  18. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Drug eluting stents for treating coronary heart disease: late stage assessment

    Awaiting development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  22. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  23. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

    Awaiting development [GID-TA11279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]

    In development [GID-TA11062] Expected publication date: 30 October 2024

    Technology appraisal guidance
    In development

  25. Atogepant for preventing migraine [ID5090]

    In development [GID-TA10992] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  26. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]

    In development [GID-TA11381] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  27. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  28. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  29. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  30. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 13 November 2024

    NICE guideline
    In development

  31. Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media

    In development [GID-NG10410] Expected publication date: 16 October 2024

    NICE guideline
    In development

  32. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  33. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    In development [GID-DG10054] Expected publication date: 10 July 2024

    Diagnostics guidance
    In development